|1.||Gallo, Richard L: 56 articles (10/2015 - 11/2002)|
|2.||Schauber, Jürgen: 20 articles (12/2014 - 03/2006)|
|3.||Agerberth, Birgitta: 18 articles (08/2015 - 06/2006)|
|4.||Nizet, Victor: 15 articles (10/2015 - 01/2003)|
|5.||Gudmundsson, Gudmundur H: 10 articles (01/2015 - 06/2006)|
|6.||Ruzicka, Thomas: 10 articles (12/2014 - 12/2008)|
|7.||Yamasaki, Kenshi: 8 articles (11/2014 - 10/2006)|
|8.||Di Nardo, Anna: 8 articles (11/2014 - 02/2005)|
|9.||Gallo, R L: 8 articles (06/2014 - 10/2001)|
|10.||Zanetti, Margherita: 7 articles (09/2006 - 01/2004)|
06/01/2012 - "Taken together, our findings demonstrate that the natural cathelicidin peptide OH-CATH30 and its analogs exhibit relatively low toxicity and potent efficacy in mouse models, indicating that they may have therapeutic potential against the systemic infections caused by drug-resistant bacteria."
11/01/2002 - "These results indicate that cathelicidin is secreted in human sweat, has potent anti-microbial activity against both gram-positive and gram-negative bacteria, and can, after processing from the preproform, provide a barrier for protection against infection. "
01/01/2014 - "Furthermore, although cathelicidin-deficient mice had an intact early cellular inflammatory response, later phase neutrophil response to infection was absent in these animals, with significantly impaired clearance of P. "
02/01/2015 - "The antimicrobial peptide cathelicidin-BF could be a potential therapeutic for Salmonella typhimurium infection."
01/01/2014 - "Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo."
05/01/2006 - "We investigated the efficacy of LL-37, the C-terminal part of the only cathelicidin in humans identified to date (termed human cationic antimicrobial protein), in three experimental rat models of gram-negative sepsis. "
12/15/2006 - "Together, our data suggest that the protective effect of LzMPC in sepsis is related to an enhanced cathelicidin-related innate immunity in macrophages. "
01/01/2005 - "Human cathelicidin LL-37 inhibits the binding of endotoxin lipopolysaccharide (LPS) to CD14-positive cells and could ameliorate sepsis. "
05/01/1995 - "Human CAP18(104-140) or a derivative peptide may have therapeutic potential for bacterial sepsis."
01/01/2011 - "The cathelicidin bovine myeloid antimicrobial peptide 28 (BMAP-28) has broad antimicrobial activities and confers protection in animal models of bacterial infection or sepsis. "
11/01/2013 - "Phenylbutyrate treatment reduced clinical illness, improved histological features of inflammation and up-regulated CAP-18 in the epithelia. "
02/01/2015 - "Considering the important role of mast cells in inflammation, the aim of this study was to determine whether LL-37, human-derived cathelicidin, can induce mast cell activation. "
01/15/2011 - "In this study, we show that keratinocyte autophagy negatively regulates p62 expression, which is essential for the prevention of excessive inflammation and the induction of cathelicidin in human keratinocytes. "
05/01/2008 - "Our animal study showed that antibacterial peptide 'cathelicidin' increased mucus thickness and prevented inflammation in the colon. "
01/01/2008 - "These studies demonstrate the role of cathelicidin as a central factor in the pathogenesis of cutaneous inflammation. "
|4.||Bacterial Infections (Bacterial Infection)
10/01/2012 - "Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections."
12/01/2009 - "Induction of AMPs such as LL-37 of the cathelicidin family might provide a novel approach in treating bacterial infections. "
08/01/2007 - "The human cathelicidin LL-37, for example, has modest direct antimicrobial activity under physiological conditions, but has been demonstrated to have potent antiendotoxin activity in animal models, as well as the ability to resolve certain bacterial infections. "
06/01/2006 - "The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection."
05/01/2006 - "The antimicrobial protein cathelicidin is considered to play an important role in the defense mechanisms against bacterial infection. "
02/01/2013 - "Whether endogenous cathelicidin is protective against ulcerative colitis, however, is unclear. "
07/01/2012 - "Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis."
05/04/2015 - "The objective is to develop the new found cathelicidin-BF as a therapeutic to patients of ulcerative colitis. "
02/01/2013 - "Cathelicidin gene therapy: a new therapeutic option in ulcerative colitis and beyond?"
06/01/2007 - "A new role for cathelicidin in ulcerative colitis in mice."
|7.||Anti-Bacterial Agents (Antibiotics)
|9.||Leukocyte Elastase (Neutrophil Elastase)
|10.||RNAIII inhibiting peptide
|3.||Transplantation (Transplant Recipients)
|4.||Heterologous Transplantation (Xenotransplantation)